PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 154 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is 1.14 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $26,000 | -62.3% | 6,400 | -42.9% | 0.01% | -38.5% |
| Q3 2018 | $69,000 | -46.1% | 11,200 | -29.1% | 0.01% | -55.2% |
| Q2 2018 | $128,000 | +190.9% | 15,800 | +163.3% | 0.03% | +163.6% |
| Q1 2018 | $44,000 | -25.4% | 6,000 | -31.0% | 0.01% | +22.2% |
| Q2 2017 | $59,000 | -79.0% | 8,700 | -70.8% | 0.01% | -71.9% |
| Q1 2017 | $281,000 | -7.3% | 29,800 | -15.1% | 0.03% | -15.8% |
| Q4 2016 | $303,000 | +131.3% | 35,100 | +16.5% | 0.04% | +153.3% |
| Q1 2016 | $131,000 | -31.1% | 30,136 | -2.9% | 0.02% | -37.5% |
| Q4 2015 | $190,000 | +153.3% | 31,036 | +136.9% | 0.02% | +166.7% |
| Q3 2015 | $75,000 | – | 13,100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
| Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
| BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
| Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
| TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
| SEARLE & CO. | 60,000 | $349,000 | 0.34% |
| TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
| RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
| Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
| TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |